Overall, there is clear evidence that targeting ATG4B can provide a benefit in cancer, and there is particularly good evidence for breast cancer, lung cancer, colorectal cancer, and pancreatic ductal adenocarcinoma. The gene discussed is ATG4B; the disease is pancreatic ductal adenocarcinoma.